Tegavivint is under clinical development by Iterion Therapeutics and currently in Phase II for Osteosarcoma. According to GlobalData, Phase II drugs for Osteosarcoma have a 13% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Tegavivint’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Tegavivint overview

Tegavivint (BC-2059) is under development for the treatment of relapsed or refractory c-Myc-overexpressing large B-cell lymphomas, desmoid tumors, metastatic epidermal growth factor receptor (EGFR)-positive non-small cell lung cancer (NSCLC), acute myelocytic leukemia, multiple myeloma, solid tumors including osteosarcoma, r/r non-Hodgkin lymphoma and desmoid tumors, Ewing sarcoma, liver tumors (hepatocellular carcinoma [HCC] and hepatoblastoma), osteosarcoma, Wilms tumor, acute myeloid leukemia, colorectal cancer and idiopathic pulmonary fibrosis. The drug candidate is administered through oral and intravenous route. It is a small molecule anthraquinone oxime-analog. It acts by targeting transducin beta-like protein 1. It was also under development for cancer, pancreatic cancer, ovarian cancer, chronic myelocytic leukemia (CML, Chronic Myeloid Leukemia), myelodysplastic syndrome.

Iterion Therapeutics overview

Iterion Therapeutics is a venture-backed, clinical stage biotechnology company developing novel targeted cancer therapeutics. The company is headquartered in Houston, Texas, the US.

For a complete picture of Tegavivint’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 15 September 2023

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.